Jeffrey T Schouten

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
  2. pmc Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095
    Jeffrey T Schouten
    University of Washington, Seattle, USA
    Clin Infect Dis 50:787-91. 2010
  3. doi request reprint Factors associated with remaining on initial randomized efavirenz-containing regimens
    Marlene Smurzynski
    aCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts bFred Hutchinson Cancer Research Center, Seattle, Washington cUniversity of Washington, Seattle, Washington dNorthwestern University Feinberg School of Medicine, Division of Infectious Diseases, Chicago, Illinois eBirmingham Veterans Affairs Medical Center and University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    AIDS 27:1887-97. 2013
  4. pmc Evidence for limited genetic compartmentalization of HIV-1 between lung and blood
    Laura Heath
    Department of Microbiology, University of Washington, Seattle, WA, USA
    PLoS ONE 4:e6949. 2009
  5. ncbi request reprint Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio
    Kathleen Mulligan
    University of California at San Francisco, San Francisco General Hospital, San Francisco, California, USA
    AIDS 21:47-57. 2007
  6. doi request reprint Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
  7. doi request reprint Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008

Detail Information

Publications7

  1. pmc A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
    ..The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss...
  2. pmc Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095
    Jeffrey T Schouten
    University of Washington, Seattle, USA
    Clin Infect Dis 50:787-91. 2010
    ..Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 ...
  3. doi request reprint Factors associated with remaining on initial randomized efavirenz-containing regimens
    Marlene Smurzynski
    aCenter for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts bFred Hutchinson Cancer Research Center, Seattle, Washington cUniversity of Washington, Seattle, Washington dNorthwestern University Feinberg School of Medicine, Division of Infectious Diseases, Chicago, Illinois eBirmingham Veterans Affairs Medical Center and University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    AIDS 27:1887-97. 2013
    ..Efavirenz (EFV) along with two nucleoside reverse transcriptase inhibitors (NRTIs) is a recommended initial antiretroviral regimen. Understanding characteristics related to EFV success is clinically useful...
  4. pmc Evidence for limited genetic compartmentalization of HIV-1 between lung and blood
    Laura Heath
    Department of Microbiology, University of Washington, Seattle, WA, USA
    PLoS ONE 4:e6949. 2009
    ..The unique environment of the lung, rich in alveolar macrophages and with specialized local immune responses, may contribute to differential evolution or selection of HIV-1...
  5. ncbi request reprint Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio
    Kathleen Mulligan
    University of California at San Francisco, San Francisco General Hospital, San Francisco, California, USA
    AIDS 21:47-57. 2007
    ..To evaluate the effects of metformin and rosiglitazone, alone or in combination, on fat distribution, insulin sensitivity, and lipids in HIV-infected patients with insulin resistance and changes in fat distribution...
  6. doi request reprint Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts
    Heather J Ribaudo
    Center for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 197:1006-10. 2008
    ..There were no significant differences among subgroups with respect to treatment responses. These results demonstrate the potency of efavirenz-containing regimens across a spectrum of pretreatment VLs and CD4 counts...
  7. doi request reprint Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008